HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression.
Humans
Carcinoma, Pancreatic Ductal
/ pathology
Pancreatic Neoplasms
/ pathology
Antigens, CD
/ metabolism
Antigens, Differentiation, Myelomonocytic
/ metabolism
Receptors, Cell Surface
/ metabolism
Male
Female
Middle Aged
Homeodomain Proteins
/ metabolism
Disease Progression
Aged
Biomarkers, Tumor
/ metabolism
Prognosis
Tumor-Associated Macrophages
/ metabolism
Adult
Immunohistochemistry
CD163
HOXA9
Pancreatic ductal adenocarcinoma
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
26
08
2024
accepted:
09
10
2024
medline:
27
10
2024
pubmed:
27
10
2024
entrez:
27
10
2024
Statut:
epublish
Résumé
The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevance of HOXA9 and CD163 in PDAC progression. Selected 98 PDAC and 98 adjacent non tumor tissues as a control group were immunostained with HOXA9 and CD163 antibodies. PDAC displayed highly significant higher HOXA9 staining intensity, percent and H score values than control group. HOXA9 staining of PDAC cases showed significant associations with poor prognostic indicators including larger tumor size, higher grade and advanced stage. PDAC showed highly significant differences regarding CD163 macrophage-specific staining intensity, percent and H score values than control group. CD163 showed significant higher expressions with larger tumor size, higher histological grade and advanced stage group. HOXA9 staining in PDAC showed highly significant direct correlations with CD163 positive macrophages. Follow up of PDAC cases revealed that high median H score of HOXA9 and CD163 were significantly associated with worse overall survival. CD163 was an independent prognostic marker of worse survival. In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevance of HOXA9 and CD163 in PDAC progression.
MATERIALS AND METHODS
METHODS
Selected 98 PDAC and 98 adjacent non tumor tissues as a control group were immunostained with HOXA9 and CD163 antibodies.
RESULTS
RESULTS
PDAC displayed highly significant higher HOXA9 staining intensity, percent and H score values than control group. HOXA9 staining of PDAC cases showed significant associations with poor prognostic indicators including larger tumor size, higher grade and advanced stage. PDAC showed highly significant differences regarding CD163 macrophage-specific staining intensity, percent and H score values than control group. CD163 showed significant higher expressions with larger tumor size, higher histological grade and advanced stage group. HOXA9 staining in PDAC showed highly significant direct correlations with CD163 positive macrophages. Follow up of PDAC cases revealed that high median H score of HOXA9 and CD163 were significantly associated with worse overall survival. CD163 was an independent prognostic marker of worse survival.
CONCLUSIONS
CONCLUSIONS
In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.
Identifiants
pubmed: 39462379
doi: 10.1186/s13000-024-01563-5
pii: 10.1186/s13000-024-01563-5
doi:
Substances chimiques
CD163 antigen
0
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
homeobox protein HOXA9
0
Receptors, Cell Surface
0
Homeodomain Proteins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
141Informations de copyright
© 2024. The Author(s).
Références
Stoffel EM, Brand RE, Goggins M. Pancreatic Cancer: changing Epidemiology and New approaches to Risk Assessment, early detection, and Prevention. Gastroenterology. 2023;164(5):752–65.
doi: 10.1053/j.gastro.2023.02.012
pubmed: 36804602
Leroux C, Konstantinidou G. Targeted therapies for Pancreatic Cancer: overview of current treatments and New opportunities for Personalized Oncology. Cancers (Basel). 2021;13(4):799.
doi: 10.3390/cancers13040799
pubmed: 33672917
Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. Int J Mol Sci. 2019;20(18):4504.
doi: 10.3390/ijms20184504
pubmed: 31514451
pmcid: 6770382
Osmond B, Facey COB, Zhang C, Boman BM. HOXA9 overexpression contributes to Stem Cell Overpopulation that drives Development and Growth of Colorectal Cancer. Int J Mol Sci. 2022;23(12):6799.
doi: 10.3390/ijms23126799
pubmed: 35743243
pmcid: 9224160
Liu T, Ji C, Sun Y, Bai W. HOXA9 expression is associated with advanced tumour stage and prognosis in nasopharyngeal carcinoma. Cancer Manag Res. 2021;13:4147–54.
doi: 10.2147/CMAR.S305814
pubmed: 34045901
pmcid: 8149281
Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA. 2013;110(24):9920–5.
doi: 10.1073/pnas.1305172110
pubmed: 23716660
pmcid: 3683728
Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, et al. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest. 2010;120(5):1535–50.
doi: 10.1172/JCI39534
pubmed: 20389018
pmcid: 2860938
Fu Z, Chen C, Zhou Q, Wang Y, Zhao Y, Zhao X, et al. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Cancer Lett. 2017;410:68–81.
doi: 10.1016/j.canlet.2017.09.019
pubmed: 28947139
Allavena P, Sica A, Garlanda C, Mantovani A. The Yin–Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155–61.
doi: 10.1111/j.1600-065X.2008.00607.x
pubmed: 18364000
Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (tam) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.
doi: 10.1189/jlb.0609385
pubmed: 19741157
Yoshikawa K, Mitsunaga S, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, Aizawa M, Ochiai A. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012;103(11):2012–20.
doi: 10.1111/j.1349-7006.2012.02411.x
pubmed: 22931216
pmcid: 7659389
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.
doi: 10.1038/nrclinonc.2016.217
pubmed: 28117416
pmcid: 5480600
Adsay NV, Basturk O, Bonnett M, Kilinc N, Andea AA, Feng J, Che M, Aulicino MR, Levi E, Cheng JD. A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2005;29(6):724–33.
doi: 10.1097/01.pas.0000163360.40357.f1
pubmed: 15897739
Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–7.
doi: 10.1245/s10434-017-6025-x
pubmed: 28752469
Salama S, Shoeib M, Shehata W, Hemida A. Expression of Homeobox A9 (HOXA9) in non- melanoma skin Cancer: a clinical and immunohistochemical study. Egypt J Hosp Med. 2021;83(1):1527–35.
doi: 10.21608/ejhm.2021.171399
Dawoud MM, Abd El Samie Aiad H, Kasem NS, El Khouly EA, Al-Sharaky DR. Is overexpression of CD163 and CD47 in tumour cells of breast carcinoma implicated in the recruitment of tumour-associated macrophages (TAMs) in tumour microenvironment? Immunohistochemical prognostic study. J Immunoass Immunochem. 2024;30:1–20.
Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014;9:221.
doi: 10.1186/s13000-014-0221-9
pubmed: 25432701
pmcid: 4260254
Yang M, McKay D, Pollard JW. Diverse functions of macrophages in different tumor microenvironments. Cancer Res. 2018;78:5492–503.
doi: 10.1158/0008-5472.CAN-18-1367
pubmed: 30206177
pmcid: 6171744
Imam R, Chang Q, Black M, Yu C, Cao W. CD47 expression and CD163 + macrophages correlated with prognosis of pancreatic neuroendocrine tumor. BMC Cancer. 2021;21(1):320.
doi: 10.1186/s12885-021-08045-7
pubmed: 33765961
pmcid: 7992939
Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.
doi: 10.1038/nrc704
pubmed: 11902584
Zhou L, Wang Y, Zhou M, Zhang Y, Wang P, Li X, Yang J, Wang H, Ding Z. HOXA9 inhibits HIF-1alpha-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development. Nat Commun. 2018;9(1):1480.
doi: 10.1038/s41467-018-03914-5
pubmed: 29662084
pmcid: 5902613
Li XF, Zhang HB, Huo Y. High HOXA9 gene expression predicts response to chemotherapy and prognosis of high-grade serous ovarian cancer patients. J Int Med Res. 2022;50(11):3000605221135864.
doi: 10.1177/03000605221135864
pubmed: 36366735
Shi B, Chu J, Huang T, Wang X, Li Q, Gao Q, Xia Q, Luo S. The scavenger receptor MARCO expressed by Tumor-Associated macrophages are highly Associated with Poor Pancreatic Cancer Prognosis. Front Oncol. 2021;11:771488.
doi: 10.3389/fonc.2021.771488
pubmed: 34778091
pmcid: 8586414
Qinglin F, Yu P, Xingxing Y, Ronggui L, Xianchao L, Heguagn H. Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma. J Pancreatology. 2020;3(3):147–53.
doi: 10.1097/JP9.0000000000000055
Yassen N, Shabana M, Desouky M, Badawi M, Abouelfadl D. Immunohistochemical expression of CD163 in colorectal carcinoma and its prognostic value. J Arab Soc Med Res. 2023;18(1):43–50. https://doi.org/10.4103/jasmr.jasmr_26_22 .
doi: 10.4103/jasmr.jasmr_26_22
Aggerholm-Pedersen N, Friis HN, Baad-Hansen T, Møller HJ, Sandfeld-Paulsen B. Macrophage biomarkers sCD163 and sSIRPα in serum predict mortality in Sarcoma patients. Cancers (Basel). 2023;15(5):1544.
doi: 10.3390/cancers15051544
pubmed: 36900335
Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014;184(1):271–81.
doi: 10.1016/j.ajpath.2013.09.017
pubmed: 24332016
pmcid: 3873497
Page SH, Wright EK Jr, Gama L, Clements JE. Regulation of CCL2 expression by an upstream TALE homeodomain protein-binding site that synergizes with the site created by the A-2578G SNP. PLoS ONE. 2011;6(7):e22052.
doi: 10.1371/journal.pone.0022052
pubmed: 21760952
pmcid: 3132772
Zaret KS. Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. Nat Rev Genet. 2008;9(5):329–40.
doi: 10.1038/nrg2318
pubmed: 18398419
Yan FM, Chen AS, Hao F, Zhao XP, Gu CH, Zhao LB, Yang DL, Hao LJ. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol. 2000;6(6):805–11.
doi: 10.3748/wjg.v6.i6.805
pubmed: 11819700
pmcid: 4728266
Gonçalves CS, Xavier-Magalhães A, Pojo M, Oliveira AI, Correia S, Reis RM, Sousa N, Rocha M, Costa BM. Transcriptional profiling of HOXA9-regulated genes in human glioblastoma cell models. Genom Data. 2015;5:54–8.
doi: 10.1016/j.gdata.2015.05.010
pubmed: 26484224
pmcid: 4583997
Adamaki M, Lambrou GI, Athanasiadou A, et al. HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: significant correlation with relapse and overall survival. Leuk Res. 2015;39:874–82.
doi: 10.1016/j.leukres.2015.04.012
pubmed: 26059450